Adamis’ high-dose naloxone clears FDA hurdle at last; Oyster Point wins nod in dry eye
Oct. 18, 2021
The third time proved the charm for Adamis Pharmaceuticals Corp.’s high-dose naloxone injection, Zimhi, which gained FDA approval for use in treating opioid overdose, nearly three years after the San Diego-based company first submitted an NDA.